Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Creatinine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatinine SCHEMBL11393862 | 0.98 | CRBN (0.48) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL21404084 | 0.94 | CRBN (0.48) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL2248139 | 0.90 | CRBN (0.56) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL8809815 | 0.89 | CRBN (0.61) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL7203535 | 0.89 | — | — | |
| Creatinine SCHEMBL16295 | 0.89 | — | — | |
| Creatinine SCHEMBL288087 | 0.89 | CRBN (0.61) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL8637084 | 0.87 | — | — | |
| Creatinine SCHEMBL2922002 | 0.87 | — | — | |
| Creatinine SCHEMBL21404081 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3465223-B1 | METHODS AND KITS FOR THE DERIVATIZATION OF A BIOGENIC AMINE | UNIV GRONINGEN (NL) | 2023-07-19 | — | — | EP | claimed |
| US-11619638-B2 | Methods and kits for the derivatization of a biogenic amine | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-04-04 | — | — | US | claimed |
| CN-109661581-B | Methods and kits for derivatization of biogenic amines | 格罗宁根大学 | 2023-02-03 | — | — | CN | claimed |
| US-20220341952-A1 | Methods and Kits for the Derivatization of a Biogenic Amine | ACADEMISCH ZIEKENHUIS GRONINGEN (NL) | 2022-10-27 | — | — | US | claimed |
| US-20190170776-A1 | Methods and Kits for the Derivatization of a Biogenic Amine | ACADEMISCH ZIEKENHUIS GRONINGEN (NL) | 2019-06-06 | — | — | US | claimed |
| EP-3465223-A1 | METHODS AND KITS FOR THE DERIVATIZATION OF A BIOGENIC AMINE | Rijksuniversiteit Groningen (NL) | 2019-04-10 | — | — | EP | claimed |
| WO-2017204637-A1 | METHODS AND KITS FOR THE DERIVATIZATION OF A BIOGENIC AMINE | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2017-11-30 | — | — | WO | claimed |
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | COGMOTIV FLEXCO (AT) | 2026-04-28 | — | — | US | disclosed |
| US-20260055109-A1 | IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| EP-4426686-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | The Regents of the University of California (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4230724-A1 | CULTURE MEDIUM FOR PRODUCING EXTRACELLULAR VESICLES, CULTURE MEDIUM KIT, ADDITIVE, AND METHOD FOR PRODUCING EXTRACELLULAR VESICLES | FUJIFILM Corporation (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-0145459-A2 | Process for the production of chemical compounds | GLAXO GROUP LIMITED (GB) | 1985-06-19 | — | — | EP | disclosed |
| EP-0101234-A1 | Therapeutic agent | The Boots Company PLC (GB) | 1984-02-22 | — | — | EP | disclosed |
| US-4308026-A | Agglutination inhibition immunoassay for hapten using two differently sensitized particles | MOCHIDA SEIYAKU KABUSHIKI KAISHA (JP) | 1981-12-29 | — | — | US | disclosed |
| US-4252803-A | HYPOTENSIVE AGENTS, ANALGESICS | GLAXO GROUP LIMITED (GB) | 1981-02-24 | — | — | US | disclosed |
| US-4198429-A | BRONCHOSPASMOLYTIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| US-4005089-A | ANTIDEPRESSANTS AND ANTISEROTONINE AGENTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-01-25 | — | — | US | disclosed |
| US-4005206-A | TRANQUILLIZERS, FROM TRYPTAMINE AND 3-INDOLE PYRUVIC ACID, DECARBOXYLATION | ROUSSEL-UCLAF (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | CHAT, PNMT, CHRM5 | CRBN 1476/4885TOP2A 2627/4885TOP2B 2269/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | CRBN 3663/4885TOP2A 4252/4885TOP2B 3770/4885 |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | PNMT, SLC6A3, HTR3B | CRBN 2164/4885TOP2A 2985/4885TOP2B 2607/4885 |
| US-20260055109-A1 | IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS | HTR7, HTR3B, HTR3A | CRBN 2097/4885TOP2A 1550/4885TOP2B 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.